By Ron Lanton III, Esq. | Lanton, Lanton & Sosa Law PLLC
On November 15, 2026, Summit Therapeutics announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter regarding its application for ivonescimab in combination with platinum-containing chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer who had received prior EGFR tyrosine kinase inhibitor therapy.
A Complete Response Letter indicates that the FDA has completed its review and cannot approve the application in its current form, although the manufacturer may address the identified deficiencies and seek subsequent approval.
According to Summit, the FDA determined that the progression-free survival benefit demonstrated in the HARMONi clinical trial, without a statistically significant improvement in overall survival, was insufficient to support approval.
Summit entered into a licensing agreement with Akeso in December 2022, which closed in January 2023. According to Summit's most recent quarterly filing, the agreement, as amended, provides for up to $1.05 billion in additional regulatory milestone payments and $3.51 billion in commercial milestone payments, plus low double-digit royalties on net sales.
The FDA decision raises a broader question for biotechnology executives. What happens to a licensing agreement when regulatory approval is delayed or additional clinical evidence is needed?
Who Pays for Additional Development?
A regulatory setback can change the financial assumptions under which a licensing agreement was negotiated.
If additional clinical studies are needed, the parties must determine who is responsible for funding and conducting those studies, whether existing development budgets are sufficient, and who has authority to modify the development plan.
These responsibilities can become particularly important when one company develops a product and another holds commercialization rights in multiple markets.
What Happens to Milestone Payments?
Licensing agreements frequently tie payments to clinical development, regulatory approval and commercial performance.
A delayed approval may postpone certain payments and affect projected revenue. The financial impact depends on how each milestone is defined, whether other payment obligations remain in effect, and whether milestones are tied to individual indications or geographic markets.
Executives should understand these provisions before committing capital based on anticipated regulatory decisions.
Can the Agreement Be Renegotiated?
An FDA Complete Response Letter does not automatically terminate a licensing agreement or release either party from its contractual obligations.
The agreement may contain provisions addressing development deadlines, diligence requirements, termination rights, cost-sharing arrangements and the return of licensed rights.
Management should also consider whether existing manufacturing, supply and commercialization commitments remain financially appropriate under a revised development timeline.
What Should Biotechnology Executives Consider?
Companies negotiating licensing agreements should evaluate how the proposed contract would operate if regulatory approval takes longer than anticipated, is limited to a narrower indication or requires additional investment.
These questions deserve attention during negotiations, when both parties have an opportunity to allocate responsibility for costs, decision-making and development risk.
A licensing agreement should protect the commercial interests of both parties throughout drug development, including when regulatory outcomes differ from initial expectations.
About Our Services
Lanton, Lanton & Sosa Law PLLC advises pharmaceutical and biotechnology companies on licensing agreements, commercial transactions, regulatory matters and outside general counsel services.
Lanton Strategies International B.V., based in Amsterdam, provides strategic advisory services on pharmaceutical pricing, reimbursement, market access and commercialization across the United States, United Kingdom and European Union.
Together, the firms support life sciences companies throughout development, commercialization and international expansion.
This article is for general informational purposes and does not constitute legal advice.